Complete the post-activity assessment by answering each of the 10 questions with the best answer. You must answer a minimum of 7 out of 10 correctly to successfully complete the post-activity assessment and be able to complete the evaluation and application for credit.
0 of 10 questions completed
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 10 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
What is the most common subtype of non-Hodgkin lymphoma?
In the Zuma trial, there was inconsistent results across key covariates including; refractory subgroup, age, and disease stage:
Patients receiving ‘bridging chemotherapy’ were not included in the following clinical trial(s):
Cytokine Release Syndrome may cause all of the following symptoms except:
__________ typically occurs within 24 – 48 hours of CART infusion and may last up to two weeks.
The following is not correlated with the incidence of CRS or neurotoxicity:
Tisagenlecleucel or (Kymriah®) is currently approved for:
CAR T-cells may destroy CD19 antigens on B-cells, leaving patients with decreased immune functions and more susceptible to illness. For these patients, consider supplementing to keep IgG levels greater than:
Pediatric patients with ALL who relapse after frontline chemotherapy have a poor prognosis, with a five-years overall survival of:
Monitoring patients on CAR T-cell Therapy includes the CARTOX scoring system which analyzes all of the following except: